Coya Therapeutics, Inc. (NasdaqCM: COYA)
Health Care · Biotechnology · US
$4.60
-7.07% today · -18.3% 1Y
Coya Therapeutics, Inc. (NasdaqCM: COYA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $116.12M and employs 8 people.
Over the last twelve months the share price has lost 18.3%, trading between 3.71 and 7.75.
Tweenvest scores Coya Therapeutics, Inc. across four factors: quality 38/100, value 39/100. Its strongest factor is value.
COYA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $116.12M
- Revenue (TTM)
- $8.02M
- P/E
- —
- EPS
- -1.09
- Dividend yield
- —
- Beta (5Y)
- 0.58
- 52-week high
- $7.75
- 52-week low
- $3.71
- Avg volume (3M)
- —
- Shares outstanding
- 23.46M
- Employees
- 8
- Next earnings
- —
About Coya Therapeutics, Inc.
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.
- ISIN
- US22407B1089
- Founded
- 2020
- Listed since
- Dec 29, 2022
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Cibus, Inc.NasdaqCM: CBUS | $118.46M | $1.42 | -8.71% |
| Nykode Therapeutics ASOB: NYKD | $117.42M | Nkr3.20 | -6.98% |
| Oncopeptides AB (publ)OM: ONCO | $117.17M | Skr2.96 | +40.74% |
| Heidelberg Pharma AGXTRA: HPHA | $116.82M | €2.23 | -5.11% |
| enGene Therapeutics Inc.NasdaqCM: ENGN | $115.94M | $1.63 | -6.07% |
| 4basebio PLCAIM: 4BB | $115.66M | £5.63 | 0.00% |
| PMV Pharmaceuticals, Inc.NasdaqGS: PMVP | $114.78M | $1.39 | -8.55% |
| Genelux CorporationNasdaqCM: GNLX | $114.72M | $2.52 | -1.56% |
Figures last refreshed Oct 11, 2026.